Alembic Pharmaceuticals Limited — Updates, 04-12-2024: Press Release

Alembic Pharmaceuticals has received USFDA Tentative Approval for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). This product is a therapeutic equivalent to Alcon's Pataday Once Daily Relief, addressing itchy eyes from allergens such as pollen and dander. The expected market size for this ophthalmic solution is approximately US$ 22 million for the period ending September 2024. With this recent approval, Alembic has reached a cumulative total of 219 ANDA approvals, which includes 192 final approvals and 27 tentative approvals, reflecting its robust pipeline and compliance with regulatory standards. This development may enhance Alembic's market positioning and revenue streams in the ophthalmic segment, indicating a positive outlook for future growth. Investors should watch closely for the product's commercial performance and its contribution to the company's overall financial health.